Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally administered single and multiple doses of CRD-733 in healthy volunteers

Next Previous
Trial Profile

A Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally administered single and multiple doses of CRD-733 in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Dec 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CRD 733 (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

Most Recent Events

  • 23 Dec 2018 New trial record
  • 20 Sep 2018 According to a Cardurion Pharmaceuticals media release, he U.S. Food and Drug Administration (FDA) has accepted the companys Investigational New Drug Application (IND) for CRD-733 in the development to improve cardiac function in heart failure patients.This trial was recently initiated.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top